Machine learning identifies plasma metabolite panels for gastric-cancer diagnosis and prognosis
In a multicenter study of 702 participants, targeted plasma metabolomics and machine learning produced a 10-metabolite gastric-cancer diagnostic model and separate 28-metabolite survival-risk model. The diagnostic model was evaluated in an independent 95-person cohort (AUROC 0.920; sensitivity 0.905, specificity 0.75) and detected stage IA disease with AUROC 0.909. Among 181 patients followed for a median 40 months, the prognostic model achieved test-set concordance index 0.83. Succinate, uridine and lactate were among diagnostic features.
Technology: LASSO, random forest and random survival forest
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The diagnostic model was evaluated in an independent 95-person cohort (AUROC 0.920; sensitivity 0.905, specificity 0.75) and detected stage IA disease with AUROC 0.909.
- Still unknown: Case-control cohorts do not establish population screening performance. External diagnostic test n=95; prognosis cohort median follow-up 40 months with right-censored outcomes. The paper says direct clinical use is premature and requires quality-control samples. Associations are not causal and no model-guided benefit was tested.
- AI role: LASSO selected ten plasma metabolites for a diagnostic model evaluated in internal and independent external cohorts. Random survival forest selected a 28-metabolite prognostic panel, evaluated in a held-out patient set.
Evidence sources: https://www.nature.com/articles/s41467-024-46043-y.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 289 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.